SLC16A1 and neoplasm: More recently, the anti-tumour drug lonidamine (LND), has been demonstrated to cooperatively inhibit L-lactate tranport by MCT1, MCT2 and MCT4 but with low potency (K0.5 of 36-40 μM) [32].